使用负载前列腺酸性磷酸酶的抗原呈递细胞进行前列腺癌免疫治疗。

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.

作者信息

Lin Amy M, Hershberg Robert M, Small Eric J

机构信息

Department of Medicine, University of California, San Francisco, San Francisco, CA 94115, USA.

出版信息

Urol Oncol. 2006 Sep-Oct;24(5):434-41. doi: 10.1016/j.urolonc.2005.08.010.

DOI:10.1016/j.urolonc.2005.08.010

PMID:16962496

Abstract

Dendritic cells from patients with cancer are deficient in number and functional activity, leading to inadequate tumor immunosurveillance as a result of poor induction of T-cell antitumor responses. Loaded dendritic cell therapy is a vaccination strategy aimed at eliciting tumor antigen-specific, T-cell immune responses. Loaded dendritic cell therapy using prostatic acid phosphatase (APC8015; Provenge, Dendreon Corp., Seattle, WA) as an immunogen has shown a survival benefit in patients with metastatic hormone-refractory prostate cancer in a randomized phase III trial. This review will summarize the prostate cancer clinical trials using APC8015 and discuss the potential future role of APC8015 in prostate cancer treatment.

摘要

癌症患者的树突状细胞在数量和功能活性上存在缺陷，由于T细胞抗肿瘤反应诱导不足，导致肿瘤免疫监视不充分。负载树突状细胞疗法是一种旨在引发肿瘤抗原特异性T细胞免疫反应的疫苗接种策略。在一项随机III期试验中，使用前列腺酸性磷酸酶（APC8015；Provenge，Dendreon公司，华盛顿州西雅图）作为免疫原的负载树突状细胞疗法已显示出对转移性激素难治性前列腺癌患者的生存益处。本综述将总结使用APC8015的前列腺癌临床试验，并讨论APC8015在前列腺癌治疗中未来的潜在作用。